Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Mustang Bio Stock Is On Fire Today

By George Budwell - Apr 18, 2019 at 10:58AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A new gene therapy could be a functional cure for "bubble boy" disease.

What happened

Shares of the tiny gene therapy company Mustang Bio ( MBIO -6.03% ) erupted higher in premarket trading this morning, gaining a jaw-dropping 358% at its peak in early-morning action. What fueled Mustang's surging stock this morning?

Mustang's shares are blasting off in response to the news that an experimental gene therapy, MB-107, for "bubble boy" disease -- also known as X-linked severe combined immunodeficiency, or XSCID for short -- reportedly cured eight boys with the deadly condition. Equally critical, Mustang said that the boys are showing no signs of unintended side effects from the therapy -- an issue that has derailed prior gene therapies for XSCID. Mustang licensed MB-107 from St. Jude Children's Research Hospital. 

Businessman sitting at desk appearing to be pleased after throwing hundred dollar bills into the air.

Image Source: Getty Images.

So what

Bubble boy disease is a rare genetic condition that results in a severely impaired immune system. As a result, patients with XSCID are extremely susceptible to infections, which often forces them to live in sterile environments. If these promising efficacy and safety results hold, however, this high-profile genetic disease might finally have a viable treatment option -- perhaps even a cure. Given this breakthrough result, it's no wonder investors are piling into this small-cap gene therapy stock today.      

Now what

Investors shouldn't get overly excited at this early juncture, however. Mustang still needs to wait for additional data prior to filing for MB-107's regulatory approval, and that's not an issue to take lightly. Many once-promising gene therapies, after all, have gone haywire at the last second.  

That's not to say that Mustang's bubble boy treatment is destined to hit a speed bump, but caution is always warranted when it comes to early-stage studies that yield seemingly game-changing results. Stated simply, Mustang's stock is arguably only suited for ultra-aggressive investors at this stage -- despite these highly encouraging trial results. 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Mustang Bio, Inc. Stock Quote
Mustang Bio, Inc.
$1.87 (-6.03%) $0.12

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/03/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.